Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoDSKYF -3.83%79 3-Year Share Buyback Ratio is 1.70 as of Jun. 2026, which is 162% above its 10-year median of 0.65. GuruFocus rates DSKYF with a GF Score™ of 79/100 and a GF Value™ of $32.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 646 Drug Manufacturers companies, Daiichinkyo Co ranks better than 95.67% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Daiichinkyo Co's current 3-Year Share Buyback Ratio was 1.70%.
The historical rank and industry rank for Daiichinkyo Co's 3-Year Share Buyback Ratio or its related term are showing as below:
DSKYF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -18.7 Med: 0.65 Max: 2.7
Current: 1.7
During the past 13 years, Daiichinkyo Co's highest 3-Year Share Buyback Ratio was 2.70%. The lowest was -18.70%. And the median was 0.65%.
DSKYF's 3-Year Share Buyback Ratio is ranked better than 95.67% of 646
companies
in the Drug Manufacturers industry
Industry Median: -2.1
vs DSKYF: 1.70
Daiichinkyo Co (OTCPK:DSKYF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Daiichinkyo Co 3-Year Share Buyback Ratio Related Terms
DSKYF vs LLY, JNJ, ABBV: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's 3-Year Share Buyback Ratio falls into.
Daiichinkyo Co 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 1.70 mean?
Daiichinkyo Co (DSKYF) has a 3-Year Share Buyback Ratio of 1.70 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Daiichinkyo Co and its competitors. This is 162% above median its historical median of 0.65. According to the industry distribution chart, Daiichinkyo Co ranks #28 out of 646 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Daiichinkyo Co's 3-Year Share Buyback Ratio too high?
Daiichinkyo Co's current 3-Year Share Buyback Ratio of 1.70 is 162% above median its 10-year median of 0.65. Based on the distribution chart, Daiichinkyo Co ranks #28 out of 646 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Daiichinkyo Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's 3-Year Share Buyback Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #28 out of 646 companies for 3-Year Share Buyback Ratio. This places Daiichinkyo Co in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Daiichinkyo Co and its competitors. Daiichinkyo Co's current 3-Year Share Buyback Ratio is 1.70, which is 162% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $32.02, compared to a current price of $17.60 — trading 45% below its estimated fair value. The current 3-Year Share Buyback Ratio is 1.70, which is 162% above median its 10-year median of 0.65. Daiichinkyo Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current 3-Year Share Buyback Ratio is 1.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSKYF) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $17.60 is trading 45% below its estimated GF Value™ of $32.02.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSKYF:
3-Year Share Buyback Ratio: 1.70 (162% above median its 10-year median of 0.65)
GF Value™: $32.02 vs. price of $17.60 (45% below fair value)
No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
79GF Score
Get the complete analysis for DSKYF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
